Načítá se...
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13
Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder,...
Uloženo v:
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2947363/ https://ncbi.nlm.nih.gov/pubmed/18824593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-04-152678 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|